EEEzel Elgun

Ezel Elgun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ezel Elgun has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience

    by Şeyma Yavuz, Vildan Ozkocaman, Vildan Gürsoy, Tuba Ersal, İbRahim Ethem Pınar, Fazıl Cagrı Hunutlu, Ezel Elgun, Fahir Özkalemkaş

    Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. It may lead to symptoms such as hyperviscosity syndrome, anemia, and neuropathy. The indication for treatment is not based on a specific IgM level but is determined according to the clinical condition. This study aimed to retrospectively evaluate the treatment responses of patients diagnosed with WM between 2019 and 2024 at the Hematology Outpatient Clinic, Department of Internal Medicine, X Hospital. A total of 29 patients were included. Demographic characteristics and first- and second-line treatment responses were analyzed. The median age at diagnosis was 78 years; 69% were male. The median follow-up duration was 58.76 months. According to the IPS risk score, 20.7% were low risk, 27.6% intermediate risk, and 51.7% high risk. Treatment was initiated in 82% of patients, with rituximab plus bendamustine (R-Benda) being the most frequently used regimen. The overall response rate to first-line therapy was 75.9%. Among laboratory parameters, hemoglobin, platelet count, and LDH were identified as predictive factors for mortality. No significant difference in survival was observed according to IPS risk score at diagnosis (p>0.05). Survival differences were assessed using Kaplan-Meier analysis. Patients who achieved a response to first-line therapy demonstrated longer survival. Conventional immunochemotherapy remains an effective and tolerable treatment option in WM. However, larger comparative studies with novel agents such as Bruton tyrosine kinase (BTK) inhibitors are needed. Treatment decisions in WM should be individualized based on patient characteristics and clinical findings.

  • Open Access

    Predicting Bleeding in AML-Associated DIC: Limitations of the ISTH Score and a Modified Approach

    by Bedrettin Orhan, Fahir Özkalemkaş, Tuba Bayır, Cumali Yalçın, Büşra Güner, Ezel Elgün, Esra Gülderen, Ayşe Bulur, Tuba Ersal, Fazıl Çağrı Hunutlu, et al.

    Background and Objectives: Bleeding is a major cause of mortality in cases of acute myeloid leukemia (AML)-associated disseminated intravascular coagulation (DIC). The predictive power of the standard International Society on Thrombosis and Hemostasis (ISTH) score for bleeding in patients diagnosed with AML is limited. This study aimed to evaluate the performance of the standard ISTH score and modified versions in predicting bleeding among acute promyelocytic leukemia (APL, M3) and non-APL AML subgroups. Methods: This single-center, retrospective study included 190 AML patients (61 APL, 129 non-APL). The predictive power of the original ISTH score and eight different modified scores—incorporating parameters such as lactate dehydrogenase (LDH) and genetic positivity—for DIC-related bleeding was assessed using receiver operating characteristic (ROC) analysis. Results: In the APL group, the original ISTH score was statistically significant in predicting DIC-related bleeding (AUC = 0.727), but the modifications did not improve performance. In the non-APL AML group, the original score did not predict bleeding (AUC = 0.632, p = 0.079). However, a modified ISTH score excluding D-dimer and including LDH (≥800 mg/dL) and genetic positivity significantly improved prediction (AUC = 0.710, p = 0.005). This modification increased specificity from 48.2% to 60.7% and sensitivity from 76.5% to 82.4%. Conclusions: A subtype-specific approach is required to predict bleeding risk in AML-associated DIC. Modified ISTH scores remain suboptimal for APL; however, a modified score incorporating LDH and genetic status represents a promising tool to identify non-APL AML patients at risk of bleeding and warrants prospective validation.


  • Open Access

    Prognostic Value of Inflammation and Nutrition-Based Scores in Low-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study

    by Tuba Ersal, Vildan Özkocaman, Sinem Çubukçu, Tuba Güllü Koca, Fazıl Çağrı Hunutlu, Şeyma Yavuz, Ezel Elgün, Gökhan Ocakoğlu, Fahir Özkalemkaş

    Background/Objectives: The pathogenesis of Myelodysplastic Syndrome (MDS) is diverse; however, increasing evidence suggests that inflammation and oxidative stress play a significant role in the development and progression of the disease. This study aimed to evaluate the prognostic impact of inflammation, nutritional status, and oxidative stress at diagnosis in patients with low-risk MDS. Methods: A retrospective analysis was conducted on 175 newly diagnosed low-risk MDS patients. Results: A low Prognostic Nutritional Index (PNI) and a high systemic oxidative stress (SOS) score were independently associated with poorer prognosis (PNI: HR 1.598, 95% CI 1.076–2.372, p = 0.02; SOS: HR 1.003, 95% CI 1.001–1.006, p = 0.002). The optimal PNI cut-off value for predicting mortality was identified as 47.47. Based on this cut-off, 92 patients had a low PNI score, while 83 patients had a high PNI score. The comparison between these groups revealed a statistically significant difference in median overall survival (OS), with 45.5 months for the low-PNI group and 75.1 months for the high-PNI group (p < 0.001). However, PNI was not significantly associated with progression to acute myeloid leukemia (AML) (p = 0.668). In the multivariate OS analysis, several factors were identified as independent predictors of prognosis, including a high Revised International Prognostic Scoring System (R-IPSS) score, low PNI, high SOS score, advanced age, male gender, and transformation to AML. Conclusions: Together, PNI and SOS may serve as simple, accessible tools to improve risk stratification in low-risk MDS patients.


  • Open Access

    Could PTH/Ca Ratio Serve as a New Marker for Evaluating Bone Metabolism in Hemophilia Patients?

    by Tuba Ersal, Fazıl Çağrı Hunutlu, Vildan Gürsoy, Ezel Elgün, Şeyma Yavuz, İpek Dal Akkuş, İlayda Baş, Vildan Özkocaman, Fahir Özkalemkaş

    Background/Objectives: Low bone mineral density (BMD) is common in hemophilia patients. Identifying high-risk patients for low BMD early is essential to prevent complications and reduce morbidity. The parathyroid hormone (PTH)/calcium (Ca) ratio is a cost-effective marker for predicting BMD, highlighting the need for routine screening and early intervention in this population. Hemophilia is a hereditary bleeding disorder caused by deficiencies in clotting factors VIII (hemophilia A) and IX (hemophilia B). Patients with hemophilia are at risk of low bone mineral density (BMD). This study aimed to evaluate the prevalence of low BMD, associated risk factors, and raise awareness regarding its significance in hemophilia patients. Methods: We retrospectively assessed bone metabolism in 62 hemophilia patients followed at our center. BMD was evaluated using dual-energy X-ray absorptiometry (DEXA). Additionally, serum levels of 25-OH-D3, alkaline phosphatase, PTH, Ca, phosphor, and creatinine were measured. The PTH/Ca, PTH/25-OH-D3, and Ca×25-OH-D3/PTH ratios were calculated. Results: The median age of the 62 patients with hemophilia included in the study (hemophilia A: 87.1%, hemophilia B: 12.9%) was 37 years (range: 21–66), and all were male. Of these patients, 67.7% (n = 42) had severe, 21% (n = 13) had moderate, and 11.3% (n = 7) had mild hemophilia. A total of 85.5% of patients were on factor prophylaxis, and 75.4% had a target joint. In laboratory analysis, the median 25-OH-D3 level was 13.4 µg/L and 75% patients had 25-OH-D3 deficiency. According to DEXA results, 62.9% had lower than normal BMD. When we divided the patients into normal and low BMD groups according to DEXA results, weight (p = 0.006), height (p = 0.024), factor levels (p = 0.004), PTH (p = 0.010), AST (p = 0.029), and PTH/Ca (p = 0.011) levels were statistically significantly different between the groups. The severity of the disease and the rate of receiving prophylaxis were higher in the group with low BMD (p = 0.015, p = 0.006, respectively). In multivariate analysis, PTH/Ca ratio and weight were found to be independent risk factors for BMD. A linear relationship was found between PTH/Ca ratio and BMD. The optimal cut-off value for PTH/Ca was 6.57, with a selectivity of 65% and specificity of 82%. When we divided the patients into groups according to the cut-off value of 6.57, we found that the probability of low BMD increased approximately 7-fold in the group with PTH/Ca > 6.57 (OR 7.045, 95% CI 1.485–33.42, p = 0.014). There was an inverse association between patient weight and low BMD (p = 0.043). Conclusions: Low BMD is a critical public health concern frequently observed in patients with hemophilia. The study highlights a high rate of low BMD and 25-OH-D3 deficiency in hemophilia patients, with the PTH/Ca ratio shown to be useful in predicting BMD. The PTH/Ca ratio is suggested as an accessible, cost-effective, and practical test for evaluating BMD in hemophilia patients.

  • Open Access

    Modified Endothelial Activation and Stress Index: A New Predictor for Survival Outcomes in Classical Hodgkin Lymphoma Treated with Doxorubicin-Bleomycin-Vinblastine-Dacarbazine-Based Therapy

    by Fazıl Çağrı Hunutlu, Hikmet Öztop, Vildan Gürsoy, Tuba Ersal, Ezel Elgün, Şeyma Yavuz, Selin İldemir Ekizoğlu, Azim Ali Ekizoğlu, Vildan Özkocaman, Fahir Özkalemkaş

    Background: Although the cure rates of classical Hodgkin Lymphoma (cHL) are as high as 90% using the current treatment protocols, the prognosis is poor for primary refractory patients. Thus, a biomarker that can predict patients with early progression at the time of diagnosis is an unmet clinical need. Endothelial activation and stress index (EASIX) and its variant modified EASIX (mEASIX) is a scoring system currently used for the prediction of prognosis in hematologic malignancies. This study aimed to investigate the prognostic value of the mEASIX score in newly diagnosed cHL patients. Methods: Data from 206 patients who underwent positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy for cHL between January 2007 and November 2023 were retrospectively analyzed. The prognostic value of the mEASIX score was evaluated using the receiver operating characteristic (ROC) analysis, Cox regression analysis, and the Kaplan–Meier method, and then compared with standard risk assessment methods. Results: The median age at diagnosis was 33 years, and the rate of patients in the advanced stage was 67%. ROC analysis determined an optimal mEASIX score cut-off of 17.28, categorizing patients into mEASIXhigh (47%) and mEASIXlow (53%) groups. The 5-year progression-free survival (PFS) (60% vs. 84.3%) and overall survival (OS) (79.6% vs. 95.8%) were significantly lower in the mEASIXhigh group (p < 0.001). Additionally, multivariate analysis showed that the independent variables affecting PFS included the nodular sclerosing subtype (HR: 0.4), bone marrow involvement (HR: 2.6), and elevated mEASIX (HR: 3.1). Independent variables, which had an effect on OS included elevated mEASIX (HR:3.8) and higher IPS-3 scores (HR:1.9). Furthermore, a higher mEASIX score (≥17.28) was identified as an independent variable indicating primary refractory disease (OR: 6.5). Conclusions: mEASIX is a powerful and easy-to-access marker for the detection of primary refractory disease and prognosis in newly diagnosed cHL cases.


  • Open Access

    Lenfomalı Hastalarda Otolog Kök Hücre Nakli Hazırlık Rejimi Olarak BuCy-E ve BEAM Protokollerinin Retrospektif Karşılaştırılması

    by Tuba Güllü Koca, Vildan Ozkocaman, Sinem Çubukçu, Fazıl Cagrı Hunutlu, Şeyma Yavuz, Ezel Elgun, Tuba Ersal, Fahir Özkalemkaş

    Bu çalışma, relaps/refrakter malign lenfomalarda kullanılan otolog kök hücre nakli (OKİT) için iki farklı hazırlık rejimi olan BuCy-E ve BEAM'in etkinliği ve toksisite profillerini karşılaştırmaktadır. BuCy-E ve BEAM, lenfoma tedavisinde yaygın olarak kullanılan iki hazırlık rejimidir ve bu çalışmada her iki rejimin kısa dönem sonuçları retrospektif olarak incelenmiştir. On ikisi Hodgkin Lenfoma (HL) ve 18'i Non-Hodgkin Lenfoma (NHL) tanısı alan toplam 30 hasta çalışmaya alınmıştır. Hastaların demografik özellikleri, tedavi yanıtları, yan etkiler ve toksisiteleri kaydedilmiştir. Elde edilen bu veriler her iki rejim için istatistiksel olarak karşılaştırılmıştır. Her iki grup arasında yaş, cinsiyet ve tanı açısından anlamlı bir fark bulunmamıştır. Febril nötropeni BEAM grubunda istatistiksel olarak daha yüksek oranda bulunmasına rağmen fungal enfeksiyonlar arasındaki fark istatistiksel anlamlılığa ulaşamamıştır. BEAM grubunda şiddetli mukozit daha sık görülmüştür. Her iki grupta bulantı, kusma ve diyare benzer seviyelerde görülmüştür. BEAM grubu, median PFS açısından BuCy-E’ye göre anlamlı şekilde daha üstün bulunmuştur (23 ay vs. 12 ay, p = 0.0044). Median OS’de ise BEAM grubu daha avantajlı görünmekle birlikte (23 ay vs. 12 ay), bu fark istatistiksel olarak anlamlı değildir (p = 0.179). BuCy-E ve BEAM rejimleri, kısa dönem toksisite profilleri açısından karşılaştırılabilir olup, BEAM rejimi PFS açısından üstün bir sağkalım sunmaktadır. Ancak, BEAM rejiminde febril nötropeni gibi yan etkilerin daha sık gözlenmesi dikkate alınmalıdır. OS açısından gruplar arasında istatistiksel olarak anlamlı bir fark bulunmamakla birlikte, uzun dönem sonuçlar için daha geniş hasta gruplarında ve uzun süreli takiplerle yapılacak prospektif çalışmalara ihtiyaç vardır. BuCy-E rejimi, daha düşük toksisite profili nedeniyle belirli hasta gruplarında etkin bir alternatif olarak değerlendirilebilir.

  • Relaps/Refrakter Hodgkin Lenfoma Hastalarının Otolog Hematopoetik Kök Hücre Nakil Sonuçları ve Risk Faktörü Etkilerinin Retrospektif Değerlendirilmesi

    by Ezel Elgun, Vildan Gürsoy, Tuba Ersal, İbRahim Ethem Pinar, Fahir Özkalemkaş, Vildan Ozkocaman

    Otolog hematopoetik kök hücre nakli (OHKHN) relaps/refrakter Hodgkin lenfoma (HL) için kurtarma tedavisi sonrasında uygulanılan standart bir tedavidir. Çalışma ile merkezimizdeki relaps/refrakter HL tanılı OHKHN uygulanılan hastaların hastalıksız (DFS) ve genel sağkalım (OS) saptamasını ve risk faktörlerinin sağkalım üzerindeki etkisini incelenmeyi amaçladık. Merkezimizde Ocak 2009–Mart 2020 tarihleri arasında takipli OHKHN uygulanılan 314 hastanın 35 (%11)’i HL tanılıydı. Çalışmaya relaps/refrakter HL tanılı 18 yaşından büyük OHKHN uygulanılan 35 hasta dahil edildi. Hastaların %46’sı kadındı. Medyan tanı yaşı 29 (14-62) ve nakil yaşı 33 (22-62)’idi. Primer kemoterapi sonrasında hastaların %66’sında remisyon sağlanırken %34’ü refrakter kaldı. Relaps/refrakter HL’ye uygulanılan kurtarma tedavisi sonucunda %6 parsiyel yanıt, %26 tam yanıt, %68 refrakter kabul edildi. OHKHN sonrası hastaların %49’unda remisyon sağlanırken, %51’inde relaps gelişti. OHKHN sonrasında relaps olan hastaların tedavi yanıtında %39’u remisyon, %17’si refrakter, %44’ü hayatını kaybetti. Hayatını kaybeden hastaların %88'i lenfoma kaynaklı, %12’si lenfoma harici nedenden kaybedildi. OHKHN sonrası hastaların ortalama OS 99(±8,9) ay; DFS 60(±10,7) aydı. OHKHN sonrası relaps süresi 12 ay altında (p=0,033) ve relaps anındaki sedimentasyon düzeyinin normal olması (p=0,021) DFS için anlamlı; relaps anında LDH düzeyinin normal olması (p=0,022) OS için anlamlı olduğu saptandı. Çok değişkenli analizde OS üzerinde etkili prognostik risk faktörü saptanmadı. Diğer taraftan DFS üzerinde; hemoglobin düzeyinde bir birimlik artışın relaps riskini 1,67 kat arttırdığı, nötrofil engraftmanında bir birimlik artışın relaps riskini %30 ve relaps süresi 12 ay üzerinde olmasının relaps riskini %85 düzeyinde azalttığı saptandı. Çalışmamızda hastaların birkaç risk faktörünün OHKHN sağkalımı ve süresi üzerinde etkili olduğunu saptadık. Ancak daha anlamlı sonuçlar için çalışmaların örneklem grubunun genişletilmesi ve takip süresinin uzatılması gerekmektedir.

  • Open Access

    A Case of Hairy Cell Leukemia Diagnosed by Leukocyoclastic Vasculitis Symptoms

    by Ezel Elgun, Belkis Nihan Coskun, Bedrettin Orhan, Fahir Özkalemkaş, Yavuz Pehli̇van

    Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disease. LSV is characterized by inflammation of small vessels. Its association is rare in the literature and HCL can be seen in LSV etiology, although the relationship between the 2 diseases is far from clear. Here, we aimed to present a case with constitutional symptoms, palpable purpuric lesions on the body and diagnosed as HCL from bone marrow biopsy.